SAN FRANCISCO — West Coast teams from Latham & Watkins and Cooley advised on the reverse merger of biopharmaceutical company Transcept Pharmaceuticals and Paratek Pharmaceuticals.

Point Richmond, Calif.-based Transcept is a publicly traded company that’s struggled to monetize an insomnia drug. Boston-based Paratek, on the other hand, is a privately held company with a Phase III antibiotic whose plans for an initial public offering were scuttled last year.